Ken Griffin Spring Works Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $182,628 - $243,732	5,700 Added 183.87%	8,800 $281,000
Q2 2024 Aug 14, 2024	SELL	$36.06 - $47.62 $1.5 Million - $1.98 Million	-41,500 Reduced 93.05%	3,100 $116,000
Q1 2024 May 15, 2024	BUY	$36.5 - $52.5 $357,700 - $514,500	9,800 Added 28.16%	44,600 $2.2 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $607,974 - $1.2 Million	32,100 Added 1188.89%	34,800 $1.27 Million
Q3 2023 Nov 14, 2023	SELL	$23.12 - $31.38 $143,344 - $194,556	-6,200 Reduced 69.66%	2,700 $62,000
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $92,600 - $130,840	4,000 Added 81.63%	8,900 $233,000
Q1 2023 May 15, 2023	SELL	$24.97 - $34.05 $1.04 Million - $1.42 Million	-41,600 Reduced 89.46%	4,900 $126,000
Q4 2022 Feb 14, 2023	SELL	$21.73 - $28.72 $734,474 - $970,736	-33,800 Reduced 42.09%	46,500 $1.21 Million
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $1.07 Million - $1.76 Million	44,400 Added 123.68%	80,300 $2.29 Million

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.6B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.